The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Calcimimetic Market Research Report 2024
Synopsis
A calcimimetic is a pharmaceutical drug that mimics the action of calcium on tissues, by allosteric activation of the calcium-sensing receptor that is expressed in various human organ tissues. Calcimimetics are used to treat secondary hyperparathyroidism (SHPT).
Global Calcimimetic market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Calcimimetic market research.
The parathyroid gland is an essential gland for human life, and SHPT is a common and serious decompensation disease in patients with chronic kidney disease receiving dialysis treatment, and it is one of the important manifestations of mineral metabolism disorders. According to the 2012 China Epidemiological Survey, the number of patients with middle and end-stage renal disease in China is about 2 million, the dialysis rate is less than 20%, and the conversion rate of SHPT in patients with mineral and bone metabolic disorders (CKD-MBD) is close to 50%. . The dialysis rate is 90% in developed countries (United States, Europe, Japan). Based on this, it can be predicted that in the future, the number of SHPT people will release a large growth space with the improvement of the diagnosis, detection and treatment of chronic kidney disease.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Calcimimetic market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Amgen
Ono Pharmaceutical
Aurobindo Pharma
Roche Holding AG
Lilly
Merck & Co., Inc.
Johnsons & Johnsons
Bristol Myers Squibb
Accord Healthcare , Inc.
Alkem Labs
Viatris
Teva Pharmaceutical Industries Ltd
Segment by Type
Cinacalcet
Etelcalcetide
Evocalcet
Segment by Application
Hospital
Clinic
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Calcimimetic report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
A calcimimetic is a pharmaceutical drug that mimics the action of calcium on tissues, by allosteric activation of the calcium-sensing receptor that is expressed in various human organ tissues. Calcimimetics are used to treat secondary hyperparathyroidism (SHPT).
Global Calcimimetic market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Calcimimetic market research.
The parathyroid gland is an essential gland for human life, and SHPT is a common and serious decompensation disease in patients with chronic kidney disease receiving dialysis treatment, and it is one of the important manifestations of mineral metabolism disorders. According to the 2012 China Epidemiological Survey, the number of patients with middle and end-stage renal disease in China is about 2 million, the dialysis rate is less than 20%, and the conversion rate of SHPT in patients with mineral and bone metabolic disorders (CKD-MBD) is close to 50%. . The dialysis rate is 90% in developed countries (United States, Europe, Japan). Based on this, it can be predicted that in the future, the number of SHPT people will release a large growth space with the improvement of the diagnosis, detection and treatment of chronic kidney disease.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Calcimimetic market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Amgen
Ono Pharmaceutical
Aurobindo Pharma
Roche Holding AG
Lilly
Merck & Co., Inc.
Johnsons & Johnsons
Bristol Myers Squibb
Accord Healthcare , Inc.
Alkem Labs
Viatris
Teva Pharmaceutical Industries Ltd
Segment by Type
Cinacalcet
Etelcalcetide
Evocalcet
Segment by Application
Hospital
Clinic
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Calcimimetic report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Index1 Calcimimetic Market Overview
1.1 Product Overview and Scope of Calcimimetic
1.2 Calcimimetic Segment by Type
1.2.1 Global Calcimimetic Market Value Comparison by Type (2023-2029)
1.2.2 Cinacalcet
1.2.3 Etelcalcetide
1.2.4 Evocalcet
1.3 Calcimimetic Segment by Application
1.3.1 Global Calcimimetic Market Value by Application: (2023-2029)
1.3.2 Hospital
1.3.3 Clinic
1.4 Global Calcimimetic Market Size Estimates and Forecasts
1.4.1 Global Calcimimetic Revenue 2018-2029
1.4.2 Global Calcimimetic Sales 2018-2029
1.4.3 Global Calcimimetic Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Calcimimetic Market Competition by Manufacturers
2.1 Global Calcimimetic Sales Market Share by Manufacturers (2018-2023)
2.2 Global Calcimimetic Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Calcimimetic Average Price by Manufacturers (2018-2023)
2.4 Global Calcimimetic Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Calcimimetic, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Calcimimetic, Product Type & Application
2.7 Calcimimetic Market Competitive Situation and Trends
2.7.1 Calcimimetic Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Calcimimetic Players Market Share by Revenue
2.7.3 Global Calcimimetic Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Calcimimetic Retrospective Market Scenario by Region
3.1 Global Calcimimetic Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Calcimimetic Global Calcimimetic Sales by Region: 2018-2029
3.2.1 Global Calcimimetic Sales by Region: 2018-2023
3.2.2 Global Calcimimetic Sales by Region: 2024-2029
3.3 Global Calcimimetic Global Calcimimetic Revenue by Region: 2018-2029
3.3.1 Global Calcimimetic Revenue by Region: 2018-2023
3.3.2 Global Calcimimetic Revenue by Region: 2024-2029
3.4 North America Calcimimetic Market Facts & Figures by Country
3.4.1 North America Calcimimetic Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Calcimimetic Sales by Country (2018-2029)
3.4.3 North America Calcimimetic Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Calcimimetic Market Facts & Figures by Country
3.5.1 Europe Calcimimetic Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Calcimimetic Sales by Country (2018-2029)
3.5.3 Europe Calcimimetic Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Calcimimetic Market Facts & Figures by Country
3.6.1 Asia Pacific Calcimimetic Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Calcimimetic Sales by Country (2018-2029)
3.6.3 Asia Pacific Calcimimetic Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Calcimimetic Market Facts & Figures by Country
3.7.1 Latin America Calcimimetic Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Calcimimetic Sales by Country (2018-2029)
3.7.3 Latin America Calcimimetic Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Calcimimetic Market Facts & Figures by Country
3.8.1 Middle East and Africa Calcimimetic Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Calcimimetic Sales by Country (2018-2029)
3.8.3 Middle East and Africa Calcimimetic Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Calcimimetic Sales by Type (2018-2029)
4.1.1 Global Calcimimetic Sales by Type (2018-2023)
4.1.2 Global Calcimimetic Sales by Type (2024-2029)
4.1.3 Global Calcimimetic Sales Market Share by Type (2018-2029)
4.2 Global Calcimimetic Revenue by Type (2018-2029)
4.2.1 Global Calcimimetic Revenue by Type (2018-2023)
4.2.2 Global Calcimimetic Revenue by Type (2024-2029)
4.2.3 Global Calcimimetic Revenue Market Share by Type (2018-2029)
4.3 Global Calcimimetic Price by Type (2018-2029)
5 Segment by Application
5.1 Global Calcimimetic Sales by Application (2018-2029)
5.1.1 Global Calcimimetic Sales by Application (2018-2023)
5.1.2 Global Calcimimetic Sales by Application (2024-2029)
5.1.3 Global Calcimimetic Sales Market Share by Application (2018-2029)
5.2 Global Calcimimetic Revenue by Application (2018-2029)
5.2.1 Global Calcimimetic Revenue by Application (2018-2023)
5.2.2 Global Calcimimetic Revenue by Application (2024-2029)
5.2.3 Global Calcimimetic Revenue Market Share by Application (2018-2029)
5.3 Global Calcimimetic Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Amgen
6.1.1 Amgen Corporation Information
6.1.2 Amgen Description and Business Overview
6.1.3 Amgen Calcimimetic Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Amgen Calcimimetic Product Portfolio
6.1.5 Amgen Recent Developments/Updates
6.2 Ono Pharmaceutical
6.2.1 Ono Pharmaceutical Corporation Information
6.2.2 Ono Pharmaceutical Description and Business Overview
6.2.3 Ono Pharmaceutical Calcimimetic Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Ono Pharmaceutical Calcimimetic Product Portfolio
6.2.5 Ono Pharmaceutical Recent Developments/Updates
6.3 Aurobindo Pharma
6.3.1 Aurobindo Pharma Corporation Information
6.3.2 Aurobindo Pharma Description and Business Overview
6.3.3 Aurobindo Pharma Calcimimetic Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Aurobindo Pharma Calcimimetic Product Portfolio
6.3.5 Aurobindo Pharma Recent Developments/Updates
6.4 Roche Holding AG
6.4.1 Roche Holding AG Corporation Information
6.4.2 Roche Holding AG Description and Business Overview
6.4.3 Roche Holding AG Calcimimetic Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Roche Holding AG Calcimimetic Product Portfolio
6.4.5 Roche Holding AG Recent Developments/Updates
6.5 Lilly
6.5.1 Lilly Corporation Information
6.5.2 Lilly Description and Business Overview
6.5.3 Lilly Calcimimetic Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Lilly Calcimimetic Product Portfolio
6.5.5 Lilly Recent Developments/Updates
6.6 Merck & Co., Inc.
6.6.1 Merck & Co., Inc. Corporation Information
6.6.2 Merck & Co., Inc. Description and Business Overview
6.6.3 Merck & Co., Inc. Calcimimetic Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Merck & Co., Inc. Calcimimetic Product Portfolio
6.6.5 Merck & Co., Inc. Recent Developments/Updates
6.7 Johnsons & Johnsons
6.6.1 Johnsons & Johnsons Corporation Information
6.6.2 Johnsons & Johnsons Description and Business Overview
6.6.3 Johnsons & Johnsons Calcimimetic Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Johnsons & Johnsons Calcimimetic Product Portfolio
6.7.5 Johnsons & Johnsons Recent Developments/Updates
6.8 Bristol Myers Squibb
6.8.1 Bristol Myers Squibb Corporation Information
6.8.2 Bristol Myers Squibb Description and Business Overview
6.8.3 Bristol Myers Squibb Calcimimetic Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Bristol Myers Squibb Calcimimetic Product Portfolio
6.8.5 Bristol Myers Squibb Recent Developments/Updates
6.9 Accord Healthcare , Inc.
6.9.1 Accord Healthcare , Inc. Corporation Information
6.9.2 Accord Healthcare , Inc. Description and Business Overview
6.9.3 Accord Healthcare , Inc. Calcimimetic Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Accord Healthcare , Inc. Calcimimetic Product Portfolio
6.9.5 Accord Healthcare , Inc. Recent Developments/Updates
6.10 Alkem Labs
6.10.1 Alkem Labs Corporation Information
6.10.2 Alkem Labs Description and Business Overview
6.10.3 Alkem Labs Calcimimetic Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Alkem Labs Calcimimetic Product Portfolio
6.10.5 Alkem Labs Recent Developments/Updates
6.11 Viatris
6.11.1 Viatris Corporation Information
6.11.2 Viatris Calcimimetic Description and Business Overview
6.11.3 Viatris Calcimimetic Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Viatris Calcimimetic Product Portfolio
6.11.5 Viatris Recent Developments/Updates
6.12 Teva Pharmaceutical Industries Ltd
6.12.1 Teva Pharmaceutical Industries Ltd Corporation Information
6.12.2 Teva Pharmaceutical Industries Ltd Calcimimetic Description and Business Overview
6.12.3 Teva Pharmaceutical Industries Ltd Calcimimetic Sales, Revenue and Gross Margin (2018-2023)
6.12.4 Teva Pharmaceutical Industries Ltd Calcimimetic Product Portfolio
6.12.5 Teva Pharmaceutical Industries Ltd Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Calcimimetic Industry Chain Analysis
7.2 Calcimimetic Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Calcimimetic Production Mode & Process
7.4 Calcimimetic Sales and Marketing
7.4.1 Calcimimetic Sales Channels
7.4.2 Calcimimetic Distributors
7.5 Calcimimetic Customers
8 Calcimimetic Market Dynamics
8.1 Calcimimetic Industry Trends
8.2 Calcimimetic Market Drivers
8.3 Calcimimetic Market Challenges
8.4 Calcimimetic Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
